Good points ,, the offer was for Non Neural that LCT received an offer in 2017 to support the company to complete a clinical trial of transplantation of NTCELL to validate it as a treatment for a non-neurology related application that has a current overall treatment market of USD4.9b per annum.We understand that MedSafe would allow a PhaseII study and that there is a large global unmet need for such a potential treatment for the targeted application.....
I would have thought the company would have announced such a commercial offer? especially for application outside Neural...
That was news to me ,,did anyone else know of this offer??
Good points ,, the offer was for Non Neural that LCT received an...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add 1AI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
-0.001(12.5%) |
Mkt cap ! $11.81M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.8¢ | 0.7¢ | $21.26K | 3.022M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 8514049 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 1168300 | 11 |
View Market Depth
| Last trade - 16.10pm 11/09/2024 (20 minute delay) ? |
| 1AI (ASX) Chart |